New Percutaneous Devices to Prevent Embolism in Atrial Fibrillation

Patients with atrial fibrillation (AF) unsuitable for anticoagulation because of bleeding risk, require other strategies to prevent stroke. For some years, there have been in the market (limited to some places; not as part of the regular agenda of cardiologists and hematologists) devices to occlude the atrium that have been proved safe and effective.

Proliferan los dispositivos para el reemplazo valvular mitral por catéter

These new devices are a completely different. They are permanent filters placed directly in both carotid arteries and are designed to capture >1.4 mm emboli.

This non-randomized, multicenter study has shown for the first time in humans the feasibility and safety of implanting this bilateral filter in patients with AF, high bleeding risk (CHA2DS2-VASc ≥ 2) unsuitable for anticoagulation, with common carotid arteries between 4.8 and 9.8 mm and stenosis < 30%.


Read also: The First Antidote Against Ticagrelor Is a Rapid-Acting, Extended Effect Agent in Preliminary Results.


Under ultrasound guidance and after direct puncture of the carotid with a 24 G needle, the filter is unfurled in the artery with a motorized system. All patients received aspirin and clopidogrel for 3 months, and aspirin thereafter.

Primary end points were procedural success (correct implantation of filter in both carotids) and composite of events at 30 days (death, stroke, major bleeding, filter migration, thrombus formation or stenosis). Ultrasound follow-up was carried out immediately after procedure, prior to discharge, at one week, one month and 3, 6 and 12 months.

The study included 25 patients with mean CHA2DS2-VASc of 4.4 ± 1, half of them had presented prior embolism.

Procedural success was 92%, in one patient, the device could be deployed only in one artery. There were no procedure related major events, only 20% of hematomas were puncture related.


Read also: El primer antídoto del ticagrelor es rápido y de acción prolongada en los resultados preliminares.


After 6 months, no patients formed thrombi inside the filter, but 4 did capture emboli (one bilateral); none of these patients developed symptoms.

In all patients, thrombi were reabsorbed using low molecular weight heparin for some time. There were 2 minor strokes, but not in carotid territory.

Conclusión

The implantation of permanent carotid filters to prevent strokes is technically feasible and safe.

Original Title: A Percutaneous Permanent Carotid Filter for Stroke Prevention in Atrial Fibrillation: The CAPTURE Trial.

Reference: Vivek Y et al. Journal of the American College of Cardiology (2019). ACCEPTED MANUSCRIPT.

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Supera vs. Eluvia at 3 Years in Severely Calcified Femoropopliteal Lesions

Severe calcification remains one of the main predictors of restenosis and the need for repeat revascularization following endovascular treatment of femoropopliteal disease. In this...

Is abdominal aortic aneurysm screening cost-effective in women?

Although ultrasound screening for abdominal aortic aneurysm (AAA) is a well-established strategy in men over 65 years of age, its value in women remains...

Aneurysm Sac Regression Predicts Better Clinical Outcomes After EVAR?

Aneurysm sac regression following endovascular abdominal aortic aneurysm repair (EVAR) has been proposed as a marker of favorable remodeling and effective aneurysm exclusion. However,...

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Shortened DAPT Regimens According to the PRECISE-HBR Score

The optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention depends on balancing the prevention of ischemic events against the risk of...

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...